VALIDATED EXECUTIVE ENGAGEMENTS
OUTREACH
8824
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1233
Interactions with Platform & by Email
PARTICIPANTS
263
Unique # Participated
VALIDATIONS
118
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
JUL 2020
TABLES
108
PAGES
188
EDITION
15
PRICE
USD $5450
Tapping into New Geographical Markets is a Great Way to Grow!
What's Your Addressable Opportunity in the Liver Cancer Drugs Market?
Amid the COVID-19 crisis, the global market for Liver Cancer Drugs estimated at US$702.9 Million in the year 2020, is projected to reach a revised size of US$2.3 Billion by 2027, growing at aCAGR of 18.4% over the period 2020-2027. Targeted Therapy, one of the segments analyzed in the report, is projected to record 19.4% CAGR and reach US$1.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Immunotherapy segment is readjusted to a revised 16.8% CAGR for the next 7-year period.
The Liver Cancer Drugs market in the U.S. is estimated at US$189 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$552.3 Million by the year 2027 trailing a CAGR of 23.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.2% and 16.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 14.6% CAGR.We bring years of research experience to this 15th edition of our report. The 188-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Bayer AG; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Exelixis, Inc.; Merck & Co., Inc.
» Drug Class (Targeted Therapy, and Immunotherapy)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » Spain » Russia » and Rest of Europe » Asia-Pacific » Australia » India » South Korea » and Rest of Asia-Pacific » Latin America » Argentina » Brazil » Mexico » and Rest of Latin America » Middle East » Iran » Israel » Saudi Arabia » United Arab Emirates » and Rest of Middle East » and Africa
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Global Competitor Market Shares |
| Liver Cancer Drugs Competitor Market Share Scenario Worldwide (in %): 2019 & 2028 |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| Liver Cancer Drugs Global Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Liver Cancer Drugs Global Retrospective Market Scenario in US$ Thousand by Region/Country: 2009-2017 |
| Liver Cancer Drugs Market Share Shift across Key Geographies Worldwide: 2009 VS 2019 VS 2025 |
| Targeted Therapy (Drug Class) World Market by Region/Country in US$ Thousand: 2018 to 2025 |
| Targeted Therapy (Drug Class) Historic Market Analysis by Region/Country in US$ Thousand: 2009 to 2017 |
| Targeted Therapy (Drug Class) Market Share Breakdown of Worldwide Sales by Region/Country: 2009 VS 2019 VS 2025 |
| Immunotherapy (Drug Class) Potential Growth Markets Worldwide in US$ Thousand: 2018 to 2025 |
| Immunotherapy (Drug Class) Historic Market Perspective by Region/Country in US$ Thousand: 2009 to 2017 |
| Immunotherapy (Drug Class) Market Sales Breakdown by Region/Country in Percentage: 2009 VS 2019 VS 2025 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| United States |
| Market Facts & Figures |
| US Liver Cancer Drugs Market Share (in %) by Company: 2019 & 2025 |
| United States Liver Cancer Drugs Market Estimates and Projections in US$ Thousand by Drug Class: 2018 to 2025 |
| Liver Cancer Drugs Market in the United States by Drug Class: A Historic Review in US$ Thousand for 2009-2017 |
| United States Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Canada |
| Canadian Liver Cancer Drugs Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018 to 2025 |
| Canadian Liver Cancer Drugs Historic Market Review by Drug Class in US$ Thousand: 2009-2017 |
| Liver Cancer Drugs Market in Canada: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Japan |
| Japanese Market for Liver Cancer Drugs: Annual Sales Estimates and Projections in US$ Thousand by Drug Class for the Period 2018-2025 |
| Liver Cancer Drugs Market in Japan: Historic Sales Analysis in US$ Thousand by Drug Class for the Period 2009-2017 |
| Japanese Liver Cancer Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| China |
| Chinese Liver Cancer Drugs Market Growth Prospects in US$ Thousand by Drug Class for the Period 2018-2025 |
| Liver Cancer Drugs Historic Market Analysis in China in US$ Thousand by Drug Class: 2009-2017 |
| Chinese Liver Cancer Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Europe |
| Market Facts & Figures |
| European Liver Cancer Drugs Market: Competitor Market Share Scenario (in %) for 2019 & 2025 |
| European Liver Cancer Drugs Market Demand Scenario in US$ Thousand by Region/Country: 2018-2025 |
| Liver Cancer Drugs Market in Europe: A Historic Market Perspective in US$ Thousand by Region/Country for the Period 2009-2017 |
| European Liver Cancer Drugs Market Share Shift by Region/Country: 2009 VS 2019 VS 2025 |
| European Liver Cancer Drugs Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018-2025 |
| Liver Cancer Drugs Market in Europe in US$ Thousand by Drug Class: A Historic Review for the Period 2009-2017 |
| European Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| France |
| Liver Cancer Drugs Market in France by Drug Class: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| French Liver Cancer Drugs Historic Market Scenario in US$ Thousand by Drug Class: 2009-2017 |
| French Liver Cancer Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Germany |
| Liver Cancer Drugs Market in Germany: Recent Past, Current and Future Analysis in US$ Thousand by Drug Class for the Period 2018-2025 |
| German Liver Cancer Drugs Historic Market Analysis in US$ Thousand by Drug Class: 2009-2017 |
| German Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Italy |
| Italian Liver Cancer Drugs Market Growth Prospects in US$ Thousand by Drug Class for the Period 2018-2025 |
| Liver Cancer Drugs Historic Market Analysis in Italy in US$ Thousand by Drug Class: 2009-2017 |
| Italian Liver Cancer Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Kingdom |
| United Kingdom Market for Liver Cancer Drugs: Annual Sales Estimates and Projections in US$ Thousand by Drug Class for the Period 2018-2025 |
| Liver Cancer Drugs Market in the United Kingdom: Historic Sales Analysis in US$ Thousand by Drug Class for the Period 2009-2017 |
| United Kingdom Liver Cancer Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Spain |
| Spanish Liver Cancer Drugs Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018 to 2025 |
| Spanish Liver Cancer Drugs Historic Market Review by Drug Class in US$ Thousand: 2009-2017 |
| Liver Cancer Drugs Market in Spain: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Russia |
| Russian Liver Cancer Drugs Market Estimates and Projections in US$ Thousand by Drug Class: 2018 to 2025 |
| Liver Cancer Drugs Market in Russia by Drug Class: A Historic Review in US$ Thousand for 2009-2017 |
| Russian Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Europe |
| Rest of Europe Liver Cancer Drugs Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018-2025 |
| Liver Cancer Drugs Market in Rest of Europe in US$ Thousand by Drug Class: A Historic Review for the Period 2009-2017 |
| Rest of Europe Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Asia-Pacific |
| Asia-Pacific Liver Cancer Drugs Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Liver Cancer Drugs Market in Asia-Pacific: Historic Market Analysis in US$ Thousand by Region/Country for the Period 2009-2017 |
| Asia-Pacific Liver Cancer Drugs Market Share Analysis by Region/Country: 2009 VS 2019 VS 2025 |
| Liver Cancer Drugs Market in Asia-Pacific by Drug Class: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Asia-Pacific Liver Cancer Drugs Historic Market Scenario in US$ Thousand by Drug Class: 2009-2017 |
| Asia-Pacific Liver Cancer Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Australia |
| Liver Cancer Drugs Market in Australia: Recent Past, Current and Future Analysis in US$ Thousand by Drug Class for the Period 2018-2025 |
| Australian Liver Cancer Drugs Historic Market Analysis in US$ Thousand by Drug Class: 2009-2017 |
| Australian Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| India |
| Indian Liver Cancer Drugs Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018 to 2025 |
| Indian Liver Cancer Drugs Historic Market Review by Drug Class in US$ Thousand: 2009-2017 |
| Liver Cancer Drugs Market in India: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| South Korea |
| Liver Cancer Drugs Market in South Korea: Recent Past, Current and Future Analysis in US$ Thousand by Drug Class for the Period 2018-2025 |
| South Korean Liver Cancer Drugs Historic Market Analysis in US$ Thousand by Drug Class: 2009-2017 |
| Liver Cancer Drugs Market Share Distribution in South Korea by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Asia-Pacific |
| Rest of Asia-Pacific Market for Liver Cancer Drugs: Annual Sales Estimates and Projections in US$ Thousand by Drug Class for the Period 2018-2025 |
| Liver Cancer Drugs Market in Rest of Asia-Pacific: Historic Sales Analysis in US$ Thousand by Drug Class for the Period 2009-2017 |
| Rest of Asia-Pacific Liver Cancer Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Latin America |
| Latin American Liver Cancer Drugs Market Trends by Region/Country in US$ Thousand: 2018-2025 |
| Liver Cancer Drugs Market in Latin America in US$ Thousand by Region/Country: A Historic Perspective for the Period 2009-2017 |
| Latin American Liver Cancer Drugs Market Percentage Breakdown of Sales by Region/Country: 2009, 2019, and 2025 |
| Latin American Liver Cancer Drugs Market Growth Prospects in US$ Thousand by Drug Class for the Period 2018-2025 |
| Liver Cancer Drugs Historic Market Analysis in Latin America in US$ Thousand by Drug Class: 2009-2017 |
| Latin American Liver Cancer Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| Argentina |
| Argentinean Liver Cancer Drugs Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018-2025 |
| Liver Cancer Drugs Market in Argentina in US$ Thousand by Drug Class: A Historic Review for the Period 2009-2017 |
| Argentinean Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Brazil |
| Liver Cancer Drugs Market in Brazil by Drug Class: Estimates and Projections in US$ Thousand for the Period 2018-2025 |
| Brazilian Liver Cancer Drugs Historic Market Scenario in US$ Thousand by Drug Class: 2009-2017 |
| Brazilian Liver Cancer Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Mexico |
| Liver Cancer Drugs Market in Mexico: Recent Past, Current and Future Analysis in US$ Thousand by Drug Class for the Period 2018-2025 |
| Mexican Liver Cancer Drugs Historic Market Analysis in US$ Thousand by Drug Class: 2009-2017 |
| Mexican Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Latin America |
| Rest of Latin America Liver Cancer Drugs Market Estimates and Projections in US$ Thousand by Drug Class: 2018 to 2025 |
| Liver Cancer Drugs Market in Rest of Latin America by Drug Class: A Historic Review in US$ Thousand for 2009-2017 |
| Rest of Latin America Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Middle East |
| The Middle East Liver Cancer Drugs Market Estimates and Forecasts in US$ Thousand by Region/Country: 2018-2025 |
| Liver Cancer Drugs Market in the Middle East by Region/Country in US$ Thousand: 2009-2017 |
| The Middle East Liver Cancer Drugs Market Share Breakdown by Region/Country: 2009, 2019, and 2025 |
| The Middle East Liver Cancer Drugs Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018 to 2025 |
| The Middle East Liver Cancer Drugs Historic Market by Drug Class in US$ Thousand: 2009-2017 |
| Liver Cancer Drugs Market in the Middle East: Percentage Share Breakdown of Sales by Drug Class for 2009, 2019, and 2025 |
| Iran |
| Iranian Market for Liver Cancer Drugs: Annual Sales Estimates and Projections in US$ Thousand by Drug Class for the Period 2018-2025 |
| Liver Cancer Drugs Market in Iran: Historic Sales Analysis in US$ Thousand by Drug Class for the Period 2009-2017 |
| Iranian Liver Cancer Drugs Market Share Analysis by Drug Class: 2009 VS 2019 VS 2025 |
| Israel |
| Israeli Liver Cancer Drugs Market Estimates and Forecasts in US$ Thousand by Drug Class: 2018-2025 |
| Liver Cancer Drugs Market in Israel in US$ Thousand by Drug Class: A Historic Review for the Period 2009-2017 |
| Israeli Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Saudi Arabia |
| Saudi Arabian Liver Cancer Drugs Market Growth Prospects in US$ Thousand by Drug Class for the Period 2018-2025 |
| Liver Cancer Drugs Historic Market Analysis in Saudi Arabia in US$ Thousand by Drug Class: 2009-2017 |
| Saudi Arabian Liver Cancer Drugs Market by Drug Class: Percentage Breakdown of Sales for 2009, 2019, and 2025 |
| United Arab Emirates |
| Liver Cancer Drugs Market in the United Arab Emirates: Recent Past, Current and Future Analysis in US$ Thousand by Drug Class for the Period 2018-2025 |
| United Arab Emirates Liver Cancer Drugs Historic Market Analysis in US$ Thousand by Drug Class: 2009-2017 |
| Liver Cancer Drugs Market Share Distribution in United Arab Emirates by Drug Class: 2009 VS 2019 VS 2025 |
| Rest of Middle East |
| Liver Cancer Drugs Market in Rest of Middle East: Recent Past, Current and Future Analysis in US$ Thousand by Drug Class for the Period 2018-2025 |
| Rest of Middle East Liver Cancer Drugs Historic Market Analysis in US$ Thousand by Drug Class: 2009-2017 |
| Rest of Middle East Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| Africa |
| African Liver Cancer Drugs Market Estimates and Projections in US$ Thousand by Drug Class: 2018 to 2025 |
| Liver Cancer Drugs Market in Africa by Drug Class: A Historic Review in US$ Thousand for 2009-2017 |
| African Liver Cancer Drugs Market Share Breakdown by Drug Class: 2009 VS 2019 VS 2025 |
| IV. COMPETITION |
| Total Companies Profiled : 50 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com